Medios AG (ILM1) - Total Liabilities
Based on the latest financial reports, Medios AG (ILM1) has total liabilities worth €398.53 Million EUR (≈ $465.92 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Medios AG to see how much of total assets are deployed in long-term investments.
Medios AG - Total Liabilities Trend (2009–2025)
This chart illustrates how Medios AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Medios AG assets under control.
Medios AG Competitors by Total Liabilities
The table below lists competitors of Medios AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jumbo Interactive Ltd
AU:JIN
|
Australia | AU$234.44 Million |
|
STEP Energy Services Ltd
TO:STEP
|
Canada | CA$197.86 Million |
|
Shandong Sino-Agri United Biotechnology Co Ltd
SHE:003042
|
China | CN¥2.71 Billion |
|
Jinpu Landscape Architecture Co.Ltd.
SHE:301098
|
China | CN¥1.91 Billion |
|
Vimta Labs Limited
NSE:VIMTALABS
|
India | Rs-4.57 Billion |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
India | Rs7.28 Billion |
|
Alvopetro Energy
V:ALV
|
Canada | CA$46.26 Million |
|
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
|
China | CN¥3.71 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Medios AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Medios AG balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medios AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medios AG (2009–2025)
The table below shows the annual total liabilities of Medios AG from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €388.82 Million ≈ $454.57 Million |
-8.33% |
| 2024-12-31 | €424.17 Million ≈ $495.89 Million |
+236.78% |
| 2023-12-31 | €125.95 Million ≈ $147.24 Million |
-1.54% |
| 2022-12-31 | €127.91 Million ≈ $149.54 Million |
-1.59% |
| 2021-12-31 | €129.98 Million ≈ $151.96 Million |
+149.42% |
| 2020-12-31 | €52.11 Million ≈ $60.92 Million |
+49.14% |
| 2019-12-31 | €34.94 Million ≈ $40.85 Million |
+25.15% |
| 2018-12-31 | €27.92 Million ≈ $32.64 Million |
+74.17% |
| 2017-12-31 | €16.03 Million ≈ $18.74 Million |
+16.48% |
| 2016-12-31 | €13.76 Million ≈ $16.09 Million |
+7321.68% |
| 2015-12-31 | €185.43K ≈ $216.79K |
+106.53% |
| 2014-12-31 | €89.78K ≈ $104.97K |
-60.37% |
| 2013-12-31 | €226.54K ≈ $264.85K |
-15.52% |
| 2012-12-31 | €268.14K ≈ $313.49K |
-4.48% |
| 2011-12-31 | €280.72K ≈ $328.20K |
-45.84% |
| 2010-12-31 | €518.32K ≈ $605.98K |
-117.75% |
| 2009-12-31 | €-2.92 Million ≈ $-3.41 Million |
-- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more